Chance for Polish medicines
In the Prime Minister’s opinion, the creation of the Institute of Medical Biotechnology is a milestone on the way to building the modern Polish medical industry and improving the functioning of the Polish healthcare. The Head of Government stated that the research institute had a chance to become a very modern organisation, thanks to which the level of Polish medicine and biotechnology would enter the completely new and unknown areas.
Prime Minister Mateusz Morawiecki stressed that 70% of medicines purchased in Poland came from abroad. On the other hand, in Germany and France more than 90% of medicines sold in pharmacies are German or French medicines. According to Prime Minister, the first period of Polish transformation had led to a situation where Poland is to a large extent dependent on foreign research centres.
We want to reduce this dependency. We want medicines to become cheaper and increasingly polonised – stressed the Head of Government.
Entrepreneurial state – entrepreneurial science
Through our actions within the entrepreneurial state, we want to join entrepreneurial science, as part of the institute being created – said Prime Minister Morawiecki. In his opinion, Poland is already doing well in the field of medicines, especially generics.
The Prime Minister reminded the story of the Polish Nobel Prize laureate, Maria Curie-Skłodowska, who had to go to France so as to develop her skills.
We do not want our excellent scientists to leave. This institution is largely designed to help us make the best scientists from all over the world come to our country, to help us attract talents – he stated.
The Head of Government stressed that he would like the excellent Polish scientists to develop the most innovative medical technologies which would translate positively into the health of the Poles.
Our healthcare will be more and more modern, it will be the flywheel of the economy and will serve the people – he emphasised.
PLN 500 million for research
Deputy Prime Minister Jarosław Gowin stressed that the creation of the Institute of Medical Biotechnology means investing in research on modern medicines, which is also of economic significance, as money will be invested in Polish companies.
What is important, this research will be commercialised and the funds obtained from commercialisation will be returned to research institutes and teams. They will be allocated for further research – stressed the Deputy Prime Minister and Minister of Science and Higher Education.
The operator of PLN 500 million will be ultimately the European Institute of Technology in Wrocław, which will provide administrative support. The funds for research will be allocated by competition. They may be applied for existing research teams functioning at the Polish Academy of Sciences and at Polish universities.
According to Deputy Prime Minister, the creation of the programme is the information, which should in the first place make Polish patients happy, as thanks to these funds Polish medicines for two most important diseases: cardiac diseases and cancer will be developed.
Institute of Medical Biotechnology
The aim of the programme is to efficiently promote and support the development of innovative products and diagnostic and therapeutic methods in Poland. What is also envisaged is their commercialisation, by financing and coordinating R&D activities conducted by the best scientific teams in Poland, selected by open competition, and by managing intellectual property, in the virtual Institute formula, similarly to the Flemish VIB – Virtual Institute of Biotechnology.